person · Reporting owner

BRADBURY DANIEL

Disclosed activity across 8 companies

Tapewire entity: 28241
SEC CIK: 0001236397

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CASTLE BIOSCIENCES INCCSTL · Entity 359	Director	May 28, 2026	June 01, 2026
CORCEPT THERAPEUTICS INCCORT · Entity 2620	Director	February 07, 2019	February 13, 2019
Equillium, Inc.EQ · Entity 6560	Director · CHAIRMAN	May 28, 2026	May 29, 2026
GERON CORPGERN · Entity 4989	Director	March 29, 2019	April 01, 2019
ILLUMINA, INC.ILMN · Entity 3137	Director	May 25, 2017	May 26, 2017
Vivani Medical, Inc.VANI · Entity 6636	Director	July 27, 2026	July 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CASTLE BIOSCIENCES INC

Report date May 28, 2026 · Filed June 01, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	11,766	Reported balance After 2026-05-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-28 · Grant · Acquired 11,766 · Balance 11,766 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2: The RSUs vest in full on the earlier of the (a) one-year anniversary of the date on May 28, 2027, or (b) the day immediately preceding the next Annual Meeting of Stockholders following the date of the grant.

CORCEPT THERAPEUTICS INC

Report date February 07, 2019 · Filed February 13, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBioBrit LLC	130,575	Reported balance After 2019-02-07 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-02-07 · Gift · Disposed 25,000 · Balance 130,575

Equillium, Inc.

Report date May 28, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2036-05-27	Direct	70,000	Reported balance After 2026-05-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-28 · Grant · Acquired 70,000 · Balance 70,000 F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

GERON CORP

Report date March 29, 2019 · Filed April 01, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Commmon StockSEC Table I · non-derivative	IndirectFamily Trust	51,323	Reported balance After 2019-03-29 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-03-29 · Grant · Acquired 9,036 · Balance 51,323 F1: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2019 of $1.66 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2019 of $1.66 per share.

ILLUMINA, INC.

Report date May 25, 2017 · Filed May 26, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	15,324	Ending reported balance After 2017-05-25 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2017-05-25 · Exercise / conversion · Acquired 600 · Balance 15,924 F1: The sale was made pursuant to a 10b5-1 plan. Row 2 · 2017-05-25 · Sale · Disposed 300 · Balance 15,624 F1: The sale was made pursuant to a 10b5-1 plan. F2: Weighted average sale price representing 300 shares sold ranging from $172.74 to $173.65 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Row 3 · 2017-05-25 · Sale · Disposed 300 · Balance 15,324 F1: The sale was made pursuant to a 10b5-1 plan. F3: Weighted average sale price representing 300 shares sold ranging from $173.82 to $174.09 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $71.09 · Expires 2023-05-29	Direct	1,600	Reported balance After 2017-05-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-05-25 · Exercise / conversion · Disposed 600 · Balance 1,600 F1: The sale was made pursuant to a 10b5-1 plan.

Filing footnotes · ownership attribution and instrument terms

F1: The sale was made pursuant to a 10b5-1 plan.

F2: Weighted average sale price representing 300 shares sold ranging from $172.74 to $173.65 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

F3: Weighted average sale price representing 300 shares sold ranging from $173.82 to $174.09 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

Vivani Medical, Inc.

Report date July 27, 2026 · Filed July 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2026-07-26	Direct	7,965	Reported balance After 2026-07-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-27 · Grant · Acquired 7,965 · Balance 7,965 F2: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service. F1: The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options have a 10-year term and vests quarterly through December 31, 2026, subject to the Reporting Person's continued service through each such date.

F2: Awarded pursuant to the Issuer's non-employee director compensation policy in lieu of cash retainer fees of $8,000, provided in consideration for increased committee service.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

INTERCEPT PHARMACEUTICALS, INC.

Report date November 08, 2023 · Filed November 13, 2023

Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-08 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2023-11-08 · Other · Disposed 23,548 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-08 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2023-11-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-11-08 · Other · Disposed 7,812 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: These shares are held by BioBrit, LLC ("BioBrit"). Mr. Bradbury and his spouse are the trustees and beneficiaries of a trust that is the sole member of BioBrit.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08	Direct	Reported balance After 2023-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82	Direct	Reported balance After 2023-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17	Direct	Reported balance After 2023-11-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22	Direct	Reported balance After 2023-11-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-11-08 · Disposition to issuer · Disposed 3,196 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01	Direct	Reported balance After 2023-11-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12	Direct	Reported balance After 2023-11-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25	Direct	Reported balance After 2023-11-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74	Direct	Reported balance After 2023-11-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (such date and time of such merger, the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: These shares are held by BioBrit, LLC ("BioBrit"). Mr. Bradbury and his spouse are the trustees and beneficiaries of a trust that is the sole member of BioBrit.

F3: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F6: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Nuvation Bio Inc.

Report date February 10, 2021 · Filed February 27, 2021

Section 16 reporting ended · disclosed 2021-02-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	25,000	Reported balance After 2021-02-10 transaction · row 1 1 source row Row 1 · 2021-02-10 · Exercise / conversion · Acquired 25,000 · Balance 25,000 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date.
Class B Common StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-02-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-02-10 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Class B Common Stock owned prior to the consummation of the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea"), Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc., was converted into one share of Class A Common Stock; the Class B Common Stock was convertible at any time at the election of the holder (or would have automatically converted at the time of the issuer's initial business combination if not yet converted at such time) with no expiration date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 20, 2018 Filed Jun 22, 2018 17:00 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	GrantOption to Purchase Common Stock · Derivative	2,748	$0.00 Strike: $85.12	$0.00	Disclosure SEC source: 0001144204-18-035416 · tv496983_4.xml · derivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,748 Underlying: Common Stock · 2,748 shares Expires 2028-06-20 F2 · derivative.exercise_date: All of the shares subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document
June 20, 2018 Filed Jun 22, 2018 17:00 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	GrantCommon Stock	1,787	$0.00	$0.00	Disclosure SEC source: 0001144204-18-035416 · tv496983_4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,429 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document
May 15, 2018 Filed May 17, 2018 20:36 UTC	GERON CORP GERN · Entity 4989	GrantStock Option (right to buy) · Derivative	70,000	$0.00 Strike: $3.43	$0.00	Disclosure SEC source: 0000886744-18-000031 · edgar.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-05-14 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates. Read SEC document
April 09, 2018 Filed Apr 9, 2018 19:36 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	PurchaseCommon Stock	7,812	$64.00	$499,968.00	Disclosure SEC source: 0001144204-18-019835 · tv490674_form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,642 Read SEC document
March 29, 2018 Filed Mar 30, 2018 22:03 UTC	GERON CORP GERN · Entity 4989	GrantCommon Stock	3,529	$0.00	$0.00	Disclosure SEC source: 0000886744-18-000022 · edgar.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 14,391 F1 · kind: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2018 of $4.25 per share. F1 · shares: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2018 of $4.25 per share. F1 · price: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on March 29, 2018 of $4.25 per share. Read SEC document
June 27, 2017 Filed Jun 29, 2017 21:02 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	GrantOption to Purchase Common Stock · Derivative	2,036	$0.00 Strike: $122.01	$0.00	Disclosure SEC source: 0001144204-17-035033 · v470074_form4.xml · derivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036 Underlying: Common Stock · 2,036 shares Expires 2027-06-27 F1 · derivative.exercise_date: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document
June 27, 2017 Filed Jun 29, 2017 21:02 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	GrantCommon Stock	1,423	$0.00	$0.00	Disclosure SEC source: 0001144204-17-035033 · v470074_form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,830 F1 · shares: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document
May 25, 2017 Filed May 26, 2017 22:25 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	600	$0.00 Strike: $71.09	$0.00	Disclosure SEC source: 0001127602-17-019586 · form4.xml · derivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Underlying: Common Stock · 600 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
May 25, 2017 Filed May 26, 2017 22:25 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	300	$173.95	$52,184.10	Disclosure SEC source: 0001127602-17-019586 · form4.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,324 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 300 shares sold ranging from $173.82 to $174.09 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
May 25, 2017 Filed May 26, 2017 22:25 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	300	$173.28	$51,983.10	Disclosure SEC source: 0001127602-17-019586 · form4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,624 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 300 shares sold ranging from $172.74 to $173.65 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
May 25, 2017 Filed May 26, 2017 22:25 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionCommon Stock	600	$71.09	$42,654.00	Disclosure SEC source: 0001127602-17-019586 · form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
May 24, 2017 Filed May 26, 2017 21:08 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $12.13	$0.00	Disclosure SEC source: 0000899243-17-014585 · doc4.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of May 24, 2017 over one-year period. Read SEC document
May 18, 2017 Filed May 23, 2017 00:22 UTC	ILLUMINA, INC. ILMN · Entity 3137	Tax withholdingCommon Stock	1,141	$175.89	$200,690.49	Disclosure SEC source: 0001127602-17-019069 · form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,324 Read SEC document
May 09, 2017 Filed May 11, 2017 00:49 UTC	GERON CORP GERN · Entity 4989	GrantStock Option (right to buy) · Derivative	50,000	$0.00 Strike: $2.63	$0.00	Disclosure SEC source: 0000886744-17-000026 · edgar.xml · derivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates. Read SEC document
April 07, 2017 Filed Apr 12, 2017 00:16 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	600	$0.00 Strike: $71.09	$0.00	Disclosure SEC source: 0001127602-17-014651 · form4.xml · derivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 Underlying: Common Stock · 600 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
April 07, 2017 Filed Apr 12, 2017 00:16 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	600	$172.79	$103,675.20	Disclosure SEC source: 0001127602-17-014651 · form4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,465 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 600 shares sold ranging from $172.58 to $173.11 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
April 07, 2017 Filed Apr 12, 2017 00:16 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionCommon Stock	600	$71.09	$42,654.00	Disclosure SEC source: 0001127602-17-014651 · form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
March 21, 2017 Filed Mar 23, 2017 18:14 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	600	$0.00 Strike: $71.09	$0.00	Disclosure SEC source: 0001127602-17-012757 · form4.xml · derivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Underlying: Common Stock · 600 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
March 21, 2017 Filed Mar 23, 2017 18:14 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	200	$164.03	$32,806.00	Disclosure SEC source: 0001127602-17-012757 · form4.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,465 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 200 shares sold ranging from $163.95 to $164.11 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
March 21, 2017 Filed Mar 23, 2017 18:14 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	400	$163.32	$65,327.60	Disclosure SEC source: 0001127602-17-012757 · form4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,665 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 400 shares sold ranging from $162.92 to $163.815 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
March 21, 2017 Filed Mar 23, 2017 18:14 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionCommon Stock	600	$71.09	$42,654.00	Disclosure SEC source: 0001127602-17-012757 · form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
March 10, 2017 Filed Mar 15, 2017 21:13 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GiftCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0000899243-17-007623 · doc4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · BioBrit LLC Disclosed balance after: 155,575 Read SEC document
February 17, 2017 Filed Feb 22, 2017 02:05 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	600	$0.00 Strike: $71.09	$0.00	Disclosure SEC source: 0001127602-17-007541 · form4.xml · derivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,400 Underlying: Common Stock · 600 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
February 17, 2017 Filed Feb 22, 2017 02:05 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	600	$162.80	$97,677.00	Disclosure SEC source: 0001127602-17-007541 · form4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,465 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 600 shares sold ranging from $162.45 to $163.42 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
February 17, 2017 Filed Feb 22, 2017 02:05 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionCommon Stock	600	$71.09	$42,654.00	Disclosure SEC source: 0001127602-17-007541 · form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
January 04, 2017 Filed Jan 6, 2017 23:59 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	600	$0.00 Strike: $71.09	$0.00	Disclosure SEC source: 0001127602-17-001310 · form4.xml · derivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 600 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
January 04, 2017 Filed Jan 6, 2017 23:59 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	400	$135.56	$54,223.20	Disclosure SEC source: 0001127602-17-001310 · form4.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,465 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 400 shares sold ranging from $135.31 to $135.98 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
January 04, 2017 Filed Jan 6, 2017 23:59 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	200	$133.93	$26,785.00	Disclosure SEC source: 0001127602-17-001310 · form4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,865 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 200 shares sold ranging from $133.47 to $134.38 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
January 04, 2017 Filed Jan 6, 2017 23:59 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionCommon Stock	600	$71.09	$42,654.00	Disclosure SEC source: 0001127602-17-001310 · form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
December 12, 2016 Filed Dec 15, 2016 01:09 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	600	$0.00 Strike: $71.09	$0.00	Disclosure SEC source: 0001127602-16-070056 · form4.xml · derivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 600 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
December 12, 2016 Filed Dec 15, 2016 01:09 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	400	$123.98	$49,593.20	Disclosure SEC source: 0001127602-16-070056 · form4.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,465 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 400 shares sold ranging from $123.80 to $124.28 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
December 12, 2016 Filed Dec 15, 2016 01:09 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	200	$122.31	$24,461.00	Disclosure SEC source: 0001127602-16-070056 · form4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,865 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 200 shares sold ranging from $122.20 to $122.41 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
December 12, 2016 Filed Dec 15, 2016 01:09 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionCommon Stock	600	$71.09	$42,654.00	Disclosure SEC source: 0001127602-16-070056 · form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
November 14, 2016 Filed Nov 15, 2016 23:14 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	600	$0.00 Strike: $71.09	$0.00	Disclosure SEC source: 0001127602-16-067262 · form4.xml · derivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 600 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
November 14, 2016 Filed Nov 15, 2016 23:14 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	600	$136.34	$81,802.98	Disclosure SEC source: 0001127602-16-067262 · form4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,465 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 600 shares sold ranging from $136.05 to $136.94 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
November 14, 2016 Filed Nov 15, 2016 23:14 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionCommon Stock	600	$71.09	$42,654.00	Disclosure SEC source: 0001127602-16-067262 · form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
November 07, 2016 Filed Nov 9, 2016 18:46 UTC	CORCEPT THERAPEUTICS INC CORT · Entity 2620	GiftCommon Stock	12,350	$0.00	$0.00	Disclosure SEC source: 0000899243-16-032997 · doc4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · BioBrit LLC Disclosed balance after: 165,575 Read SEC document
October 07, 2016 Filed Oct 12, 2016 00:35 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	600	$0.00 Strike: $71.09	$0.00	Disclosure SEC source: 0001127602-16-064684 · form4.xml · derivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,800 Underlying: Common Stock · 600 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
October 07, 2016 Filed Oct 12, 2016 00:35 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	200	$184.92	$36,984.00	Disclosure SEC source: 0001127602-16-064684 · form4.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,465 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 200 shares sold ranging from $184.86 to $184.98 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
October 07, 2016 Filed Oct 12, 2016 00:35 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	400	$184.07	$73,629.20	Disclosure SEC source: 0001127602-16-064684 · form4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,665 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 400 shares sold ranging from $183.62 to $184.60 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
October 07, 2016 Filed Oct 12, 2016 00:35 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionCommon Stock	600	$71.09	$42,654.00	Disclosure SEC source: 0001127602-16-064684 · form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
September 14, 2016 Filed Sep 16, 2016 23:58 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative	600	$0.00 Strike: $71.09	$0.00	Disclosure SEC source: 0001127602-16-062736 · form4.xml · derivative · entry 4 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Underlying: Common Stock · 600 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document
September 14, 2016 Filed Sep 16, 2016 23:58 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	400	$171.67	$68,668.00	Disclosure SEC source: 0001127602-16-062736 · form4.xml · nonDerivative · entry 3 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,465 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 400 shares sold ranging from $171.62 to $171.72 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
September 14, 2016 Filed Sep 16, 2016 23:58 UTC	ILLUMINA, INC. ILMN · Entity 3137	SaleCommon Stock	200	$170.40	$34,080.00	Disclosure SEC source: 0001127602-16-062736 · form4.xml · nonDerivative · entry 2 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,865 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 200 shares sold ranging from $170.08 to $170.72 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document
September 14, 2016 Filed Sep 16, 2016 23:58 UTC	ILLUMINA, INC. ILMN · Entity 3137	Exercise / conversionCommon Stock	600	$71.09	$42,654.00	Disclosure SEC source: 0001127602-16-062736 · form4.xml · nonDerivative · entry 1 BRADBURY DANIEL · CIK 0001236397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.